Drawing for GWYNTECH

USPTO serial 86569291

GWYNTECH

Reviewed by CopyMark Law Group

Reg. 5087356Status 702Renewal
Filing date
Status date
Registration date
Nov 22, 2016
Examiner
SPRUILL, DARRYL M
Law office
TMO LAW OFFICE 112

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with GWYNTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Cardiovascular agents for medical purposesACTIVEAug 2, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 13, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
May 26, 2023NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
May 26, 2023C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
May 26, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 16, 2022E815TEAS SECTION 8 & 15 RECEIVED—
Nov 22, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 22, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 18, 2016SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 15, 2016CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 5, 2016SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 5, 2016AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 20, 2016IUAFUSE AMENDMENT FILED—
Sep 20, 2016EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 18, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 16, 2016EX1GSOU EXTENSION 1 GRANTED—
Mar 16, 2016EXT1SOU EXTENSION 1 FILED—
Mar 16, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 29, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 4, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 4, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 15, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 10, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 10, 2015DOCKASSIGNED TO EXAMINER—
Mar 31, 2015MPMKNOTICE OF PSEUDO MARK E-MAILED—
Mar 30, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 23, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance